MedTrace Logo

Desensitization of Human Mast Cells: Mechanisms and Potential Utility for Preventing Anaphylaxis

NCT00868842 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2014-04-14

No results posted yet for this study

Summary

This is an open-label, single-center study of whether oral penicillin desensitization of healthy sensitive subjects results in allergen cross-desensitization of mast cells by skin testing and desensitization of peripheral blood basophils. The primary endpoint(s) will be PC3 prick skin test values to penicillin, aeroallergen(s) and codeine. Secondary endpoints will be levels of Syk in purified basophils determined by flow cytometry (mean fluorescence intensity) and basophil degranulation (% tryptase release) to anti-FcåRI and to calcium ionophore.

Conditions

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Lawrence B. Schwartz, M.D., Ph.D · Virginia Commonwealth University

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2012-05-31
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00868842 on ClinicalTrials.gov